Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

KOCHI: George (name changed), was 55-years-old when he was diagnosed with fatty liver. Since he was a teetotaller, he did not ...

Madrigal Pharmaceuticals (MDGL) announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated ...

Symptoms that are sometimes diagnosed as part of dementia might actually be related to a treatable liver condition, according to a recent study. Up to 13% of patients believed to have dementia are ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat ... drug sensitivity and treatment paradigms for the affected population. Here, Dewald et al. generated liver-specific DM1 mice ...

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...